HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic
First Financing Since $20m Seed Round In 2021
HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.
